Mechanism
MAGE-A4 (presented via HLA, recognized by an engineered TCR)
Assets acting on this target.
- Class
- Allogeneic TCR-NK cell therapy (donor NK cells transduced with an affinity-enhanced MAGE-A4 TCR plus CD3/CD8 co-receptor complex)
- Pathway
- TCR-mediated tumor antigen recognition combined with NK-cell cytotoxicity
Research
Sign in to access ResearchExplore this mechanism at different depths
Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.
0 of 0 assets
No assets match these filters.